{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:40:44Z","timestamp":1784547644718,"version":"3.55.0"},"reference-count":18,"publisher":"BMJ","issue":"3","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Arch Dis Child"],"published-print":{"date-parts":[[2019,3]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>Assessing influence of anti-adalimumab (ADA) antibodies (AAA) on serum trough ADA levels and uveitis activity in long-term ADA treatment of juvenile idiopathic arthritis (JIA)-associated uveitis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and interventions<\/jats:title><jats:p>This prospective observational study included 20 patients from a single centre treated with ADA for active uveitis refractory to conventional disease-modifying antirheumatic drugs. AAA, serum ADA trough levels and uveitis activity were evaluated at regular intervals up to 6 years.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>AAA were detected in nine patients (45%). Permanent AAA in seven were associated with undetectable ADA trough levels and loss of response (LOR). Transient AAA were detected in four with measurable ADA trough levels and response of uveitis to treatment, followed in two by permanent AAA associated with LOR. Use of concomitant immunosuppression was significantly higher in patients without AAA (p&lt;0.05).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>AAA-associated LOR frequently occurs in long-term treatment with ADA for JIA-associated uveitis. Concomitant immunosuppressive therapy significantly reduces the risk of LOR due to AAA.<\/jats:p><\/jats:sec>","DOI":"10.1136\/archdischild-2018-315060","type":"journal-article","created":{"date-parts":[[2018,7,19]],"date-time":"2018-07-19T16:28:38Z","timestamp":1532017718000},"page":"246-250","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":53,"title":["Drug monitoring in long-term treatment with adalimumab for juvenile idiopathic arthritis-associated uveitis"],"prefix":"10.1136","volume":"104","author":[{"given":"Andrea","family":"Skrabl-Baumgartner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Seidel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beate","family":"Langner-Wegscheider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Schlagenhauf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Jahnel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2018,7,19]]},"reference":[{"key":"2020050712483231000_104.3.246.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(01)00773-4"},{"key":"2020050712483231000_104.3.246.2","doi-asserted-by":"publisher","DOI":"10.1002\/art.22381"},{"key":"2020050712483231000_104.3.246.3","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kem053"},{"key":"2020050712483231000_104.3.246.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2007.01.033"},{"key":"2020050712483231000_104.3.246.5","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-012-2082-5"},{"key":"2020050712483231000_104.3.246.6","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2006.103721"},{"key":"2020050712483231000_104.3.246.7","first-page":"1146","article-title":"Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey","volume":"34","author":"Foeldvari","year":"2007","journal-title":"J Rheumatol"},{"key":"2020050712483231000_104.3.246.8","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1056\/NEJMc1708646","article-title":"Adalimumab for Uveitis in Juvenile Idiopathic Arthritis","volume":"377","author":"Ramanan","year":"2017","journal-title":"N Engl J Med"},{"key":"2020050712483231000_104.3.246.9","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1016\/j.ophtha.2016.08.025","article-title":"Adalimumab for treatment of noninfectious uveitis: immunogenicity and clinical relevance of measuring serum drug levels and antidrug antibodies","volume":"123","author":"Cordero-Coma","year":"2016","journal-title":"Ophthalmology"},{"key":"2020050712483231000_104.3.246.10","first-page":"1043","article-title":"Anti-adalimumab antibodies in juvenile idiopathic arthritis-related uveitis","volume":"35","author":"Leinonen","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"2020050712483231000_104.3.246.11","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40259-017-0231-8","article-title":"Immunogenicity of biologics in chronic inflammatory diseases: a systematic review","volume":"31","author":"Strand","year":"2017","journal-title":"BioDrugs"},{"key":"2020050712483231000_104.3.246.12","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-009-8140-3"},{"key":"2020050712483231000_104.3.246.13","doi-asserted-by":"crossref","first-page":"359","DOI":"10.3109\/03009742.2015.1022213","article-title":"Anti-adalimumab antibodies in juvenile idiopathic arthritis: frequent association with loss of response","volume":"44","author":"Skrabl-Baumgartner","year":"2015","journal-title":"Scand J Rheumatol"},{"key":"2020050712483231000_104.3.246.14","first-page":"390","article-title":"International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001","volume":"31","author":"Petty","year":"2004","journal-title":"J Rheumatol"},{"key":"2020050712483231000_104.3.246.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2005.03.057"},{"key":"2020050712483231000_104.3.246.16","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(85)34001-0"},{"key":"2020050712483231000_104.3.246.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.02.018"},{"key":"2020050712483231000_104.3.246.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2006.04.058"}],"container-title":["Archives of Disease in Childhood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/archdischild-2018-315060","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T22:13:40Z","timestamp":1601072020000},"score":1,"resource":{"primary":{"URL":"https:\/\/adc.bmj.com\/lookup\/doi\/10.1136\/archdischild-2018-315060"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,19]]},"references-count":18,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,2,19]]},"published-print":{"date-parts":[[2019,3]]}},"alternative-id":["10.1136\/archdischild-2018-315060"],"URL":"https:\/\/doi.org\/10.1136\/archdischild-2018-315060","relation":{},"ISSN":["0003-9888","1468-2044"],"issn-type":[{"value":"0003-9888","type":"print"},{"value":"1468-2044","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,19]]}}}